TriangleNCT03036098 · OUTCOME
Overall Survival (OS) in All Randomized Participants for Primary Study
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)
What was measured
This measure looks at how long all participants live after being placed into a treatment group in the primary study. Overall Survival (OS) is defined as the time between the date a participant is randomized (assigned to a treatment group) and the date of death from any cause. For participants without documentation of death, OS will be measured up to the last date the participant was known to be alive. If a participant was randomized but had no follow-up information, OS will be counted from the date of randomization. This helps to understand whether the treatment can help all participants in the study live longer.
Analysis population: All Randomized Participants - Primary Study
Groups in this outcome
Treatment 1
Participants received Nivolumab 1 mg/kg plus Ipilimumab 3 mg/kg every three weeks (Q3W) for up to 4 doses followed by Nivolumab monotherapy 480 mg every 4 weeks (Q4W) - Primary Study
Treatment 2
Participants received Standard of Care treatment every three weeks (Q3W) for up to 6 cycles - Primary Study
| Group | Source count |
|---|---|
| Treatment 1 | 349 |
| Treatment 2 | 357 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment 1 | 18.76 | Not reported | 15.05 | 21.82 | Not reported |
| Treatment 2 | 14.32 | Not reported | 12.22 | 15.87 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 15.05
- upper Limit
- 21.82
- value
- 18.76
- group Id
- OG001
- lower Limit
- 12.22
- upper Limit
- 15.87
- value
- 14.32
- denoms
- counts
- group Id
- OG000
- value
- 349
- group Id
- OG001
- value
- 357
- units
- Participants
- description
- This measure looks at how long all participants live after being placed into a treatment group in the primary study. Overall Survival (OS) is defined as the time between the date a participant is randomized (assigned to a treatment group) and the date of death from any cause. For participants without documentation of death, OS will be measured up to the last date the participant was known to be alive. If a participant was randomized but had no follow-up information, OS will be counted from the date of randomization. This helps to understand whether the treatment can help all participants in the study live longer.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants received Nivolumab 1 mg/kg plus Ipilimumab 3 mg/kg every three weeks (Q3W) for up to 4 doses followed by Nivolumab monotherapy 480 mg every 4 weeks (Q4W) - Primary Study
- id
- OG000
- title
- Treatment 1
- description
- Participants received Standard of Care treatment every three weeks (Q3W) for up to 6 cycles - Primary Study
- id
- OG001
- title
- Treatment 2
- param Type
- MEDIAN
- population Description
- All Randomized Participants - Primary Study
- reporting Status
- POSTED
- time Frame
- From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)
- title
- Overall Survival (OS) in All Randomized Participants for Primary Study
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice